Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II
| dc.rights.license | open | en_US |
| dc.contributor.author | FERRER, Florent | |
| dc.contributor.author | TETU, Pauline | |
| dc.contributor.author | DOUSSET, Lea | |
| dc.contributor.author | LEBBE, Celeste | |
| dc.contributor.author | CICCOLINI, Joseph | |
| dc.contributor.author | COMBAREL, David | |
| dc.contributor.author | MEYER, Nicolas | |
| dc.contributor.author | PACI, Angelo | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BOUCHET, Stephane | |
| dc.date.accessioned | 2024-10-11T07:00:18Z | |
| dc.date.available | 2024-10-11T07:00:18Z | |
| dc.date.issued | 2024-08-01 | |
| dc.identifier.issn | 1879-0461 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202413 | |
| dc.description.abstractEn | Real-life populations are more heterogeneous than those included in prospective clinical studies. In cancer patients, comorbidities and co-medications favor the appearance of severe adverse effects which can significantly impact quality of life and treatment effectiveness. Most of tyrosine kinase inhibitors (TKI) have been developed with flat oral dosing exposing patients to the risk of poor adherence due to side effects. Additionally, genetic or physiological factors, differences in diet, and drug-drug interactions can lead to inter-individual variability affecting treatment outcomes and increasing the risk of adverse events. Knowledge of the different factors of variability allows individualized patient management. This review examines the effects of adherence, food intake, and pharmaceutical form on the pharmacokinetics of oral TKI, as well as evaluating pharmacokinetics considerations improving TKI management. Concentration-effectiveness and concentration-toxicity data are presented for the selected TKI, and a simple therapeutic drug monitoring schema is outlined to help individualize dosing of oral TKI. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Efficacy | |
| dc.subject.en | Pharmacokinetics | |
| dc.subject.en | Therapy management | |
| dc.subject.en | Variability | |
| dc.title.en | Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II | |
| dc.title.alternative | Crit Rev Oncol Hematol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.critrevonc.2024.104385 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38810843 | en_US |
| bordeaux.journal | Critical Reviews in Oncology/Hematology | en_US |
| bordeaux.page | 104385 | en_US |
| bordeaux.volume | 200 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Les Laboratories Pierre Fabre | en_US |
| hal.identifier | hal-04738301 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-10-15T13:59:38Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Critical%20Reviews%20in%20Oncology/Hematology&rft.date=2024-08-01&rft.volume=200&rft.spage=104385&rft.epage=104385&rft.eissn=1879-0461&rft.issn=1879-0461&rft.au=FERRER,%20Florent&TETU,%20Pauline&DOUSSET,%20Lea&LEBBE,%20Celeste&CICCOLINI,%20Joseph&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||